|
Journal of Zhejiang University SCIENCE B
ISSN 1673-1581(Print), 1862-1783(Online), Monthly
2015 Vol.16 No.7 P.622-631
Anti-CD69 monoclonal antibody treatment inhibits airway inflammation in a mouse model of asthma
Abstract: Objective: Airway inflammation and airway hyper-responsiveness (AHR) are principle pathological manifestations of asthma. Cluster of differentiation 69 (CD69) is a well-known co-stimulatory factor associated with the activation, proliferation as well as apoptosis of immune cells. This study aims to examine the effect of anti-CD69 monoclonal antibody (mAb) on the pathophysiology of a mouse model of asthma. Methods: A murine model of ovalbumin (OVA)-induced allergic airway inflammation was used in this study. Briefly, mice were injected with 20 μg chicken OVA intraperitoneally on Days 0 and 14, followed by aerosol provocation with 1% (0.01 g/ml) OVA on Days 24, 25, and 26. Anti-CD69 mAb or isotype IgG was injected intraperitoneally after OVA challenge; dexamethasone (DXM) was administrated either before or after OVA challenge. AHR, mucus production, and eosinophil infiltration in the peribronchial area were examined. The levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-5 (IL-5) in bronchoalveolar lavage fluid (BALF) were also assayed as indices of airway inflammation on Day 28 following OVA injection. Results: Pretreatment with DXM together with anti-CD69 mAb treatment after OVA provocation completely inhibited AHR, eosinophil infiltration and mucus overproduction, and significantly reduced BALF IL-5. However, treatment with DXM alone after OVA challenge only partially inhibited AHR, eosinophil infiltration and mucus overproduction, and did not diminish BALF IL-5. Treatment with either DXM or anti-CD69 mAb did not alter the concentration of BALF GM-CSF. Conclusions: Anti-CD69 mAb treatment inhibits established airway inflammation as effectively as DXM pretreatment. This study provides a potential alternative therapeutic opportunity for the clinical management of asthma and its exacerbation.
Key words: Cluster of differentiation 69 (CD69), Eosinophil, Interleukin-5 (IL-5), Asthma
创新点:(1)与大多数关于哮喘的è¯ç‰©ç ”ç©¶å¤šä¸ºé€ æ¨¡å‰æå‰ç”¨è¯ä»¥é˜»æ–ç‚Žç—‡çš„è¿›å±•ç›¸æ¯”ï¼Œæœ¬ç ”ç©¶å°†æŠ—CD69å•æŠ—作用于气é“å·²ç»å½¢æˆçš„炎症,与临床上哮喘的治疗更接近;(2)抗CD69å•æŠ—的独特作用在于它特异性地作用于气é“活化的炎症细胞,与已有的哮喘è¯ç‰©ä»¥ç³–çš®è´¨æ¿€ç´ ç›¸æ¯”ï¼Œå¯èƒ½çš„全身å应少。
方法:鸡åµç™½è›‹ç™½è‡´æ•æ¿€å‘制备哮喘模型(图1),Buxco系统测试哮喘å°é¼ çš„æ°”é“高å应性(图6)。
结论:抗CD69å•å…‹éš†æŠ—体å¯æŠ‘制哮喘å°é¼ å·²ç»å½¢æˆçš„æ°”é“炎症,其作用效果与地塞米æ¾é¢„处ç†ç›¸å½“ã€‚æœ¬ç ”ç©¶ä¸ºä¸´åºŠå“®å–˜çš„æ€¥æ€§å‘作治疗和管ç†æ供了新的å¯èƒ½é¶ç‚¹ã€‚
关键è¯ç»„:
References:
Open peer comments: Debate/Discuss/Question/Opinion
<1>
DOI:
10.1631/jzus.B1400285
CLC number:
R562.2
Download Full Text:
Downloaded:
3260
Download summary:
<Click Here>Downloaded:
2051Clicked:
5062
Cited:
2
On-line Access:
2024-08-27
Received:
2023-10-17
Revision Accepted:
2024-05-08
Crosschecked:
2015-06-15